TABLE 3.

Multivariate Analysis of Predictors of ALI in LT Recipients With COVID‐19

Covariate	Univariate Analysis			Multivariate Analysis
	P Value	OR	95% CI	P Value	OR	95% CI
Age (years)	0.286	1.21	0.85‐1.71	0.009	2.06	1.20‐3.54
Female sex	0.494	0.72	0.28‐1.79	0.333	1.93	0.51‐7.33
Race, White	0.016	0.26	0.08‐0.79	0.016	0.13	0.024‐0.680
Ethnicity, Hispanic	0.035	2.82	1.09‐7.26	0.011	6.01	1.51‐23.90
Metabolic syndrome	0.024	3.65	1.20‐11.07	0.016	5.87	1.38‐24.99
Antibiotics	0.007	7.27	1.55‐34.02	0.046	6.93	1.04‐46.26
Vasopressors	0.004	4.88	1.74‐13.71	0.018	7.34	1.39‐38.52
Oxygen requirement	0.324	1.81	0.65‐5.04
Immunosuppression modified	0.156	2.07	0.81‐5.37
Hydroxychloroquine	0.157	2.250	0.74‐6.85
Azithromycin	0.312	1.8	0.68‐4.77
Any hepatotoxic	0.240	2.71	0.70‐10.46
APAP	0.223	2.000	0.78‐5.16
Statins	0.396	1.630	0.53‐4.98
Creatinine (peak during COVID‐19)	0.799	0.971	0.77‐1.22
PPI	0.815	1.140	0.45‐2.89

Bold signifies statistically significant.

Abbreviation: APAP, acetaminophen.